These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
336 related articles for article (PubMed ID: 27504842)
1. Review of the Tuberous Sclerosis Renal Guidelines from the 2012 Consensus Conference: Current Data and Future Study. Kingswood JC; Bissler JJ; Budde K; Hulbert J; Guay-Woodford L; Sampson JR; Sauter M; Cox J; Patel U; Elmslie F; Anderson C; Zonnenberg BA Nephron; 2016; 134(2):51-58. PubMed ID: 27504842 [TBL] [Abstract][Full Text] [Related]
2. Role of mTOR inhibition in the treatment of patients with renal angiomyolipomas. Coombs EJ J Am Assoc Nurse Pract; 2013 Nov; 25(11):588-96. PubMed ID: 24170533 [TBL] [Abstract][Full Text] [Related]
5. CT characteristics predict the response to everolimus or sirolimus of renal angiomyolipomas in patients with tuberous sclerosis complex. Wang W; Guo H; Shi B; Sun H; Li H; Zhang Y; Cai Y Int Urol Nephrol; 2019 Apr; 51(4):671-676. PubMed ID: 30756282 [TBL] [Abstract][Full Text] [Related]
6. Low-dose rapamycin reduces kidney volume angiomyolipomas and prevents the loss of renal function in a patient with tuberous sclerosis complex. Peces R; Peces C; Cuesta-López E; Pérez-Dueñas V; Vega-Cabrera C; Azorín S; Selgas R Nephrol Dial Transplant; 2010 Nov; 25(11):3787-91. PubMed ID: 20663789 [TBL] [Abstract][Full Text] [Related]
7. Treatment of renal angiomyolipoma in tuberous sclerosis complex (TSC) patients. Brakemeier S; Bachmann F; Budde K Pediatr Nephrol; 2017 Jul; 32(7):1137-1144. PubMed ID: 27585680 [TBL] [Abstract][Full Text] [Related]
8. Microscopic Kidney Disease in Tuberous Sclerosis Complex and Treatment With mTOR Inhibition. Kronick J; Gabril MY; House AA Am J Kidney Dis; 2023 Dec; 82(6):772-775. PubMed ID: 37532078 [TBL] [Abstract][Full Text] [Related]
9. Assessing the outcomes of everolimus on renal angiomyolipoma associated with tuberous sclerosis complex in China: a two years trial. Cai Y; Guo H; Wang W; Li H; Sun H; Shi B; Zhang Y Orphanet J Rare Dis; 2018 Mar; 13(1):43. PubMed ID: 29587809 [TBL] [Abstract][Full Text] [Related]
10. The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions. Curatolo P; Bjørnvold M; Dill PE; Ferreira JC; Feucht M; Hertzberg C; Jansen A; Jóźwiak S; Kingswood JC; Kotulska K; Macaya A; Moavero R; Nabbout R; Zonnenberg BA Drugs; 2016 Apr; 76(5):551-65. PubMed ID: 26927950 [TBL] [Abstract][Full Text] [Related]
11. Regression of renal angiomyolipomas with oral rapamycin therapy in a patient with tuberous sclerosis complex disease. Torun D; Micozkadioglu H; Gedikoglu M; Ozelsancak R; Tekkarismaz N Saudi J Kidney Dis Transpl; 2019; 30(2):545-548. PubMed ID: 31031395 [TBL] [Abstract][Full Text] [Related]
12. Renal angiomyolipoma with tuberous sclerosis complex: How it differs from sporadic angiomyolipoma in both management and care. Hatano T; Egawa S Asian J Surg; 2020 Oct; 43(10):967-972. PubMed ID: 31959574 [TBL] [Abstract][Full Text] [Related]
13. mTOR inhibitors are the first-choice therapy for renal angiomyolipomas secondary to tuberous sclerosis. Monich AG; Cunha MFMD; Barreto FC J Bras Nefrol; 2023; 45(4):503-505. PubMed ID: 37497829 [No Abstract] [Full Text] [Related]
14. Differentiation of Sporadic Versus Tuberous Sclerosis Complex-Associated Angiomyolipoma. Rabenou RA; Charles HW AJR Am J Roentgenol; 2015 Aug; 205(2):292-301. PubMed ID: 26204278 [TBL] [Abstract][Full Text] [Related]
15. Treatment of Renal Angiomyolipoma and Other Hamartomas in Patients with Tuberous Sclerosis Complex. Samuels JA Clin J Am Soc Nephrol; 2017 Jul; 12(7):1196-1202. PubMed ID: 28302901 [TBL] [Abstract][Full Text] [Related]
16. Long-term Follow-up Assessing Renal Angiomyolipoma Treatment Patterns, Morbidity, and Mortality: An Observational Study in Tuberous Sclerosis Complex Patients in the Netherlands. Eijkemans MJ; van der Wal W; Reijnders LJ; Roes KC; van Waalwijk van Doorn-Khosrovani SB; Pelletier C; Magestro M; Zonnenberg B Am J Kidney Dis; 2015 Oct; 66(4):638-45. PubMed ID: 26165440 [TBL] [Abstract][Full Text] [Related]
18. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Bissler JJ; Kingswood JC; Radzikowska E; Zonnenberg BA; Frost M; Belousova E; Sauter M; Nonomura N; Brakemeier S; de Vries PJ; Whittemore VH; Chen D; Sahmoud T; Shah G; Lincy J; Lebwohl D; Budde K Lancet; 2013 Mar; 381(9869):817-24. PubMed ID: 23312829 [TBL] [Abstract][Full Text] [Related]
19. [Clinical analyses of bilateral renal angiomyolipomas associated with tuberous sclerosis complex]. Huang Z; Li H; Ji Z; Xiao H Zhonghua Yi Xue Za Zhi; 2014 Apr; 94(12):935-7. PubMed ID: 24854916 [TBL] [Abstract][Full Text] [Related]
20. Tuberous sclerosis complex, mTOR, and the kidney: report of an NIDDK-sponsored workshop. Henske EP; Rasooly R; Siroky B; Bissler J Am J Physiol Renal Physiol; 2014 Feb; 306(3):F279-83. PubMed ID: 24226526 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]